Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27519656 | 0.78 | CA2 (0.41) | KCNA5NFE2L2GBA1KMT2ATDP1 | |
| SCHEMBL1272695 | 0.77 | CA2 (0.58) | KCNA5GBA1KMT2AKAT6ACA2 | |
| SCHEMBL4175553 | 0.77 | CA2 (0.45) | AKR1B1CA2 | |
| SCHEMBL777982 | 0.77 | PSIP1 (0.48) | KCNA5GBA1KMT2ATDP1KAT6A | |
| SCHEMBL9337554 | 0.76 | GAA (0.54) | KMT2ACA2 | |
| SCHEMBL14495116 | 0.76 | KEAP1 (0.51) | NFE2L2KMT2ATDP1LMNAL3MBTL1 | |
| SCHEMBL1148926 | 0.76 | MEN1 (0.49) | KMT2AKAT6A | |
| SCHEMBL9704703 | 0.75 | KCNA5 (0.42) | KCNA5NFE2L2GBA1KMT2ATDP1 | |
| SCHEMBL25413517 | 0.75 | APEX1 (0.58) | KMT2ATDP1CA2LMNAL3MBTL1 | |
| SCHEMBL25426560 | 0.74 | KMT2A (0.59) | KMT2ACA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-5716936-A | Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders | RHONE-POULENC RORER S.A. (FR) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | KCNA5 465/4885NFE2L2 1334/4885GBA1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.